168 lines
3.7 KiB
Plaintext
168 lines
3.7 KiB
Plaintext
fig:fig1-1
|
|
fig:fig1-2
|
|
fig:fig1-3
|
|
fig:fig1-4
|
|
fig:fig1-5
|
|
fig:fig2-1
|
|
fig:fig2-2
|
|
fig:fig2-3
|
|
fig:fig2-4
|
|
fig:fig2-5
|
|
fig:fig3-1
|
|
fig:fig3-2
|
|
fig:fig4-1
|
|
fig:fig5-1
|
|
fig:fig6-1
|
|
fig:fig6-2
|
|
fig:fig6-3
|
|
fig:fig6-4
|
|
fig:fig6-5
|
|
fig:fig6-6
|
|
fig:fig6-7
|
|
fig:fig6-a1
|
|
fig:fig7-1
|
|
fig:fig7-2
|
|
fig:fig7-3
|
|
fig:fig7-4
|
|
fig:fig8-1
|
|
fig:fig9-1
|
|
fig:fig10-1
|
|
fig:fig10-2
|
|
fig:fig10-3
|
|
fig:fig10-4
|
|
ch01-introduction
|
|
microbial-epidemiology
|
|
antimicrobial-resistance-in-microorganisms
|
|
laboratory-diagnostics
|
|
interpretation-of-raw-results
|
|
multi-drug-resistant-organisms
|
|
surveillance-programs
|
|
data-analysis-using-r
|
|
setting-for-this-thesis
|
|
aim-of-this-thesis-and-introduction-to-its-chapters
|
|
ch02-diagnostic-stewardship
|
|
introduction
|
|
case-1
|
|
case-2
|
|
the-general-concept
|
|
diagnostics
|
|
dsp-in-the-microbiological-laboratory
|
|
dsp-as-process-optimisation
|
|
multidisciplinary-aspects-of-dsp-and-infection-management
|
|
conclusion
|
|
ch03-introducing-new-method
|
|
background
|
|
standardising-amr-data-analysis
|
|
comparison-with-existing-software-methods
|
|
user-feedback
|
|
conclusion-1
|
|
ch04-amr-r-package
|
|
introduction-1
|
|
antimicrobial-resistance-data
|
|
antimicrobial-resistance-data-transformation
|
|
working-with-taxonomically-valid-microorganism-names
|
|
properties-of-microorganisms
|
|
working-with-antimicrobial-names-or-codes
|
|
properties-of-antimicrobial-agents
|
|
filtering-data-based-on-classes-of-antimicrobial-agents
|
|
working-with-antimicrobial-susceptibility-test-results
|
|
interpretative-rules-by-eucast
|
|
working-with-defined-daily-doses-ddd
|
|
enhancing-antimicrobial-resistance-data
|
|
determining-first-isolates
|
|
determining-multi-drug-resistant-organisms-mdro
|
|
multi-drug-resistant-tuberculosis
|
|
analysing-antimicrobial-resistance-data
|
|
calculation-of-antimicrobial-resistance
|
|
counts
|
|
proportions
|
|
design-decisions
|
|
reproducible-example
|
|
discussion
|
|
ch05-radar
|
|
introduction-2
|
|
background-1
|
|
objectives
|
|
methods
|
|
results
|
|
overview
|
|
application-design
|
|
development-process
|
|
workflow
|
|
customisation
|
|
discussion-1
|
|
principal-findings
|
|
conclusions
|
|
ch06-radar2
|
|
introduction-3
|
|
methods-1
|
|
study-setup
|
|
amr-data
|
|
amr-data-analysis-and-reporting
|
|
study-participants
|
|
study-execution-and-data
|
|
evaluation-and-study-data-analysis
|
|
results-1
|
|
study-participants-1
|
|
effectiveness-and-accuracy
|
|
efficiency
|
|
satisfaction
|
|
discussion-2
|
|
ch07-cons
|
|
introduction-4
|
|
materials-methods
|
|
study-setting-and-patient-cohort
|
|
microbiological-and-demographic-data
|
|
species-determination-and-antibiotic-susceptibility-testing-ast
|
|
selection-of-bacterial-isolates
|
|
eucast-rules-and-antibiotic-resistance-analysis
|
|
statistical-analysis
|
|
ethical-considerations
|
|
results-2
|
|
patients-and-included-isolates
|
|
occurrence-of-cons-species
|
|
definition-of-cons-persistence
|
|
antibiotic-resistance-analysis
|
|
glycopeptides
|
|
macrolides
|
|
fluoroquinolones
|
|
beta-lactamspenicillins
|
|
other-antibiotics
|
|
other-relevant-species
|
|
effect-of-patient-age-groups-on-antibiotic-resistance-in-cons
|
|
discussion-3
|
|
ch08-defining-mdr
|
|
introduction-5
|
|
methods-2
|
|
results-3
|
|
number-of-antibiograms-and-patients
|
|
results-of-mrgn-and-brmo-classification
|
|
discussion-4
|
|
ch09-changing-epidemiology
|
|
introduction-6
|
|
methods-3
|
|
setting
|
|
guidelines-for-patients-at-risk-for-mrsa-and-infection-prevention-and-control-measures
|
|
data-collection
|
|
ethical-statement
|
|
data-analysis
|
|
results-4
|
|
trend-and-cross-border-comparison-of-mrsa-rates
|
|
cross-border-comparison-of-healthcare-utilisation
|
|
discussion-5
|
|
ch10-multi-mdro-screening
|
|
introduction-7
|
|
methods-4
|
|
study-design
|
|
statistical-analysis-software
|
|
ethics
|
|
results-5
|
|
healthcare-structure-of-the-participating-hospitals
|
|
study-population-and-screening-samples-from-icus
|
|
prevalence-of-gram-positive-mdros-mrsa-and-vre
|
|
prevalence-of-gram-negative-mdro-3gcre-and-cre
|
|
prevalence-of-gram-negative-mdros-based-on-dutch-and-german-definitions
|
|
comparison-of-mdro-prevalence-between-nl-br-and-de-br-icus-in-university-and-non-university-hospitals
|
|
discussion-6
|
|
ch11-summary
|